Find trustworthy peptides from licensed pharmacies, and know the fair price.
A plain-language trust guide for anyone trying to find legitimate, safe peptides. We help you spot a real
licensed pharmacy, understand what is legal to compound, and know a fair price. This is information, not
medical or legal advice, and we do not sell peptides.
How to tell a real source from a scam
Licensed compounding pharmacy, not a "research chemical" vendor. If a site sells vials
labeled "research use only, not for human consumption," that is a legal dodge, not a deal. Real sources
are state-licensed 503A/503B pharmacies that dispense on a prescription.
A prescriber is involved. Legitimate peptides come through a licensed clinician who
evaluates you. No prescription, no medical oversight, is a red flag.
They can show credentials. Look for state pharmacy licensing, NABP/PCAB or LegitScript,
and a third-party certificate of analysis with a lot number. Vague origin and no business address mean walk away.
The compound is actually compoundable. Some peptides are restricted or not FDA-eligible.
Check the status of any compound below before you spend a dollar.
What a fair price looks like
The cheapest option is usually the most dangerous one. A $30 "research only" vial is not a
bargain, it is unregulated and unverified. Legitimate compounded peptides cost more because a licensed
pharmacy made them and a prescriber stands behind them, and that is the point.
Gray-market "research" vials, roughly $30 to $100. No oversight, no sterility guarantee,
no standardized dose. Avoid.
Telehealth clinics, roughly $150 to $425 per month. Convenience plus a remote prescriber.
Verify the pharmacy behind it.
In-person clinics, roughly $400 to $1,300 per cycle. Full evaluation and monitoring.
Ranges are general market observations for orientation, not quotes. Actual price depends on the
compound, dose, pharmacy, and your prescriber.
Is your peptide legal? Check its FDA status
Whether a peptide can be legally compounded changes often. Below is the current, sourced
status for 42 common peptides. The FDA's advisory committee meets in 17 days
(July 23-24, 2026) and could change several of these.
2023-09FDA established the interim Category 2 grouping placing 19 peptides in the do-not-compound bucket.
2026-02-27HHS Secretary R.F. Kennedy Jr. publicly signaled ~14 of 19 Category 2 peptides would move back toward Category 1.
2026-04-15FDA published removal of 12 peptides from Category 2. Removal is NOT authorization to compound.
2026-04-16Federal Register notice of the PCAC meeting published (distinct document from the Apr 15 removal notice).
2026-05-14FDA reported to have restored non-injectable GHK-Cu to Category 1 on the 503A bulk drug substances list.
2026-06-30Deadline to request to make an oral presentation at the July PCAC meeting.
2026-07-09Written comment submission deadline for the July PCAC meeting.
2026-07-23PCAC meeting Day 1 (FDA White Oak, Silver Spring MD). Reviews BPC-157, KPV, TB-500, MOTs-C for the 503A bulk substances list.
2026-07-24PCAC meeting Day 2. Reviews Emideltide (DSIP), Semax, Epitalon.
2027-02Second PCAC meeting expected before end of Feb 2027 for the remaining 5: LL-37, Dihexa, GHK-Cu (injectable), Melanotan II, PEG-MGF.
Recent FDA enforcement
Why the gray market is a real risk, not a scare tactic. Straight from the FDA's own record.
2026-03-03FDA warned 30 telehealth companies over illegal compounded GLP-1 marketing. FDA cited misleading claims, including implying compounded semaglutide has the 'same active ingredient' as approved brand drugs. FDA source
2026-03-31FDA sent warning letters to 7 research-peptide sellers. Named sellers marketed peptides as 'Research Use Only.' FDA rejected that label as a defense, stating website evidence showed the products were intended as drugs. FDA source
2025-09-22FDA warning letter to Revive Rx Pharmacy. The pharmacy produced HCG and Thymosin Beta-4 as biological products that are not eligible for 503A/503B compounding exemptions. FDA source
2025-05FDA ended shortage-based compounding discretion for semaglutide and tirzepatide. With the national GLP-1 shortage resolved, compounding copies of the brand drugs is no longer covered by FDA's earlier enforcement discretion absent a documented individual medical need. FDA source
Licensed compounding pharmacies
State-licensed 503A and 503B compounding pharmacies with publicly verifiable credentials.
This is public-record information for your own research, not an endorsement or a guarantee,
and we do not take a cut of any sale. Here is how to verify any pharmacy yourself
before using it.
We exclude pharmacies with recent FDA enforcement actions (currently: Revive Rx Pharmacy).
Empower Pharmacy · Houston, TX
503A503B
Ships nationwide. Dual-registered: 503A (PCAB-accredited) plus a 503B FDA-registered outsourcing facility, same Houston HQ. cGMP, ISO-classified clean rooms.
Licensed in all 50 states. Telehealth-focused; nationwide direct-to-patient shipping. Publishes QA claims (weekly potency testing). Accreditation list is from the pharmacy's own site; confirm each is current.
Multi-state (confirm coverage). 503A compounding pharmacy; provider portal via LifeFile e-prescribing. Specific accreditations not captured this pass, verify before listing them.
Launching shortly. We will email you when a peptide moves on or off the FDA compounding list,
and same-day during the July 23-24 advisory meeting. In the meantime, bookmark this page.